Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplants

Abba Zubair, R. Rymer, J. Young, U. Keeton, R. Befort, B. Nolot, C. Evans, T. Bleach, A. Torloni

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Current protocols for myeloma patients require more than one autologous transplant. We performed a retrospective study to determine the cost-effectiveness of large volume leukapheresis (LVL) compared with standard volume leukapheresis (SVL) collection when two transplants are required. We evaluated 87 patients who underwent a cumulative total of 260 LVL and SVL collections. The median product volume per collection was 356 ml for LVL, and this was significantly higher than the median product volume per collection for SVL (median 149.5 ml, P < 0.001). The median total CD34+ cell yield/kg was 6.4 × 106 for LVL and 5.2 × 106 for SVL. This difference was statistically significant (P = 0.005). Because the target CD34+ cell dose for a single transplant was 3 × 106/kg at our institution, overall the LVL yields enough CD34+ cells that could allow for two transplants. Therefore, more patients in the LVL group were able to undergo a potential second transplant. Because of the reserved cells for a second transplant, LVL patients received significantly less CD34+ cell/kg per transplant than the patients in SVL group (P 5 <0.001). As a result, LVL group had statistically significant but clinically insignificant delay in neutrophil (P = <0.001) and platelet (P = 0.02) engraftments. Additionally, using LVL instead of SVL to collect ≥6 × 106/kg CD34+ cells may potentially save $7,497 per patient. We therefore conclude that LVL is the method of choice for collection of multiple myeloma patients when two transplants are anticipated.

Original languageEnglish (US)
Pages (from-to)6-11
Number of pages6
JournalJournal of Clinical Apheresis
Volume24
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Leukapheresis
Multiple Myeloma
Transplants
Autografts

Keywords

  • Large volume leukapheresis
  • Multiple myeloma
  • Stem cell collection

ASJC Scopus subject areas

  • Hematology

Cite this

Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplants. / Zubair, Abba; Rymer, R.; Young, J.; Keeton, U.; Befort, R.; Nolot, B.; Evans, C.; Bleach, T.; Torloni, A.

In: Journal of Clinical Apheresis, Vol. 24, No. 1, 2009, p. 6-11.

Research output: Contribution to journalArticle

Zubair, Abba ; Rymer, R. ; Young, J. ; Keeton, U. ; Befort, R. ; Nolot, B. ; Evans, C. ; Bleach, T. ; Torloni, A. / Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplants. In: Journal of Clinical Apheresis. 2009 ; Vol. 24, No. 1. pp. 6-11.
@article{9498cf4465604ef4a245f47f9584ea59,
title = "Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplants",
abstract = "Current protocols for myeloma patients require more than one autologous transplant. We performed a retrospective study to determine the cost-effectiveness of large volume leukapheresis (LVL) compared with standard volume leukapheresis (SVL) collection when two transplants are required. We evaluated 87 patients who underwent a cumulative total of 260 LVL and SVL collections. The median product volume per collection was 356 ml for LVL, and this was significantly higher than the median product volume per collection for SVL (median 149.5 ml, P < 0.001). The median total CD34+ cell yield/kg was 6.4 × 106 for LVL and 5.2 × 106 for SVL. This difference was statistically significant (P = 0.005). Because the target CD34+ cell dose for a single transplant was 3 × 106/kg at our institution, overall the LVL yields enough CD34+ cells that could allow for two transplants. Therefore, more patients in the LVL group were able to undergo a potential second transplant. Because of the reserved cells for a second transplant, LVL patients received significantly less CD34+ cell/kg per transplant than the patients in SVL group (P 5 <0.001). As a result, LVL group had statistically significant but clinically insignificant delay in neutrophil (P = <0.001) and platelet (P = 0.02) engraftments. Additionally, using LVL instead of SVL to collect ≥6 × 106/kg CD34+ cells may potentially save $7,497 per patient. We therefore conclude that LVL is the method of choice for collection of multiple myeloma patients when two transplants are anticipated.",
keywords = "Large volume leukapheresis, Multiple myeloma, Stem cell collection",
author = "Abba Zubair and R. Rymer and J. Young and U. Keeton and R. Befort and B. Nolot and C. Evans and T. Bleach and A. Torloni",
year = "2009",
doi = "10.1002/jca.20190",
language = "English (US)",
volume = "24",
pages = "6--11",
journal = "Journal of Clinical Apheresis",
issn = "0733-2459",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplants

AU - Zubair, Abba

AU - Rymer, R.

AU - Young, J.

AU - Keeton, U.

AU - Befort, R.

AU - Nolot, B.

AU - Evans, C.

AU - Bleach, T.

AU - Torloni, A.

PY - 2009

Y1 - 2009

N2 - Current protocols for myeloma patients require more than one autologous transplant. We performed a retrospective study to determine the cost-effectiveness of large volume leukapheresis (LVL) compared with standard volume leukapheresis (SVL) collection when two transplants are required. We evaluated 87 patients who underwent a cumulative total of 260 LVL and SVL collections. The median product volume per collection was 356 ml for LVL, and this was significantly higher than the median product volume per collection for SVL (median 149.5 ml, P < 0.001). The median total CD34+ cell yield/kg was 6.4 × 106 for LVL and 5.2 × 106 for SVL. This difference was statistically significant (P = 0.005). Because the target CD34+ cell dose for a single transplant was 3 × 106/kg at our institution, overall the LVL yields enough CD34+ cells that could allow for two transplants. Therefore, more patients in the LVL group were able to undergo a potential second transplant. Because of the reserved cells for a second transplant, LVL patients received significantly less CD34+ cell/kg per transplant than the patients in SVL group (P 5 <0.001). As a result, LVL group had statistically significant but clinically insignificant delay in neutrophil (P = <0.001) and platelet (P = 0.02) engraftments. Additionally, using LVL instead of SVL to collect ≥6 × 106/kg CD34+ cells may potentially save $7,497 per patient. We therefore conclude that LVL is the method of choice for collection of multiple myeloma patients when two transplants are anticipated.

AB - Current protocols for myeloma patients require more than one autologous transplant. We performed a retrospective study to determine the cost-effectiveness of large volume leukapheresis (LVL) compared with standard volume leukapheresis (SVL) collection when two transplants are required. We evaluated 87 patients who underwent a cumulative total of 260 LVL and SVL collections. The median product volume per collection was 356 ml for LVL, and this was significantly higher than the median product volume per collection for SVL (median 149.5 ml, P < 0.001). The median total CD34+ cell yield/kg was 6.4 × 106 for LVL and 5.2 × 106 for SVL. This difference was statistically significant (P = 0.005). Because the target CD34+ cell dose for a single transplant was 3 × 106/kg at our institution, overall the LVL yields enough CD34+ cells that could allow for two transplants. Therefore, more patients in the LVL group were able to undergo a potential second transplant. Because of the reserved cells for a second transplant, LVL patients received significantly less CD34+ cell/kg per transplant than the patients in SVL group (P 5 <0.001). As a result, LVL group had statistically significant but clinically insignificant delay in neutrophil (P = <0.001) and platelet (P = 0.02) engraftments. Additionally, using LVL instead of SVL to collect ≥6 × 106/kg CD34+ cells may potentially save $7,497 per patient. We therefore conclude that LVL is the method of choice for collection of multiple myeloma patients when two transplants are anticipated.

KW - Large volume leukapheresis

KW - Multiple myeloma

KW - Stem cell collection

UR - http://www.scopus.com/inward/record.url?scp=63249094994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249094994&partnerID=8YFLogxK

U2 - 10.1002/jca.20190

DO - 10.1002/jca.20190

M3 - Article

C2 - 19156756

AN - SCOPUS:63249094994

VL - 24

SP - 6

EP - 11

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

SN - 0733-2459

IS - 1

ER -